DBV Technologies to Participate in Several Investor Conferences in September

DBV Technologies, a late-stage biopharmaceutical company based in Châtillon, France, will participate in several investor conferences in September. The company will present at the 2026 Cantor Global Healthcare Conference, the Citi’s 2026 Biopharma Back to School Conference, and the H.C. Wainwright 28th Annual Global Investment Conference.

At the Cantor Global Healthcare Conference, scheduled for September 9, 2026, DBV Technologies will engage in a fireside chat from 1:00pm ET. The event will be held in New York, New York. On September 10, 2026, the company will participate in one-on-one meetings during the Citi’s 2026 Biopharma Back to School Conference, also in New York. Finally, on September 15, 2026, DBV Technologies will host a fireside chat at 3:00pm ET during the H.C. Wainwright 28th Annual Global Investment Conference, with the same location.

For investors interested in viewing the fireside chats, live webcasts will be available on the company’s website in the Events section. These webcasts will be accessible for 90 days after the event.

DBV Technologies is dedicated to developing treatment options for food allergies and other significant unmet medical conditions. The company’s primary focus is on the VIASKIN® patch technology, which is currently being investigated for use in addressing peanut allergies. Peanut allergies affect millions of people, including a significant number of young children. The VIASKIN® Peanut Patch introduces microgram amounts of a biologically active compound through the skin, aiming to re-educate the immune system and desensitize individuals to allergens.

Through epicutaneous immunotherapy (EPIT), the VIASKIN® Peanut Patch seeks to modify an individual’s underlying allergy. This non-invasive treatment leverages the skin’s immune tolerizing properties to desensitize individuals to allergens. DBV Technologies is currently conducting ongoing clinical trials of the VIASKIN® Peanut Patch in both toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.

Headquartered in Châtillon, France, DBV Technologies also maintains operations in Warren, New Jersey, USA. Its shares are listed on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and its American Depositary Shares (ADSs) are traded on the Nasdaq Capital Market (DBVT, CUSIP: 23306J309).